Published in Microb Cell Fact on February 13, 2015
Recombinant antibody production evolves into multiple options aimed at yielding reagents suitable for application-specific needs. Microb Cell Fact (2015) 0.75
Optimization of construct design and fermentation strategy for the production of bioactive ATF-SAP, a saporin based anti-tumoral uPAR-targeted chimera. Microb Cell Fact (2016) 0.75
Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol Rev (2000) 5.25
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med (2001) 2.65
An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng (1993) 2.31
Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer (2008) 2.21
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol (2005) 2.16
A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal Biochem (1992) 1.78
Gene optimization is necessary to express a bivalent anti-human anti-T cell immunotoxin in Pichia pastoris. Protein Expr Purif (2002) 1.40
Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc Natl Acad Sci U S A (2011) 1.29
A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood (1993) 1.27
Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes. Proc Natl Acad Sci U S A (2014) 1.23
Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A. Proc Natl Acad Sci U S A (2012) 1.20
Compatible-solute-supported periplasmic expression of functional recombinant proteins under stress conditions. Appl Environ Microbiol (2000) 1.17
Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin. Cancer Res (2003) 1.11
Ribosome-inactivating proteins: from plant defense to tumor attack. Toxins (Basel) (2010) 1.07
Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs (2009) 1.05
Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases. Mol Cancer Ther (2010) 0.95
Value of monoclonal anti-CD22 (p135) antibodies for the detection of normal and neoplastic B lymphoid cells. Blood (1987) 0.91
A proteomic analysis of the Pichia pastoris secretome in methanol-induced cultures. Appl Microbiol Biotechnol (2011) 0.90
Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragment. Protein Eng (2003) 0.90
Pichia pastoris as a host for secretion of toxic saporin chimeras. FASEB J (2009) 0.89
An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies. Leuk Res (2014) 0.88
Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibody. Protein Sci (2003) 0.88
A cleavable adapter to reduce nonspecific cytotoxicity of recombinant immunotoxins. Int J Cancer (2003) 0.87
Response of B-cell lymphoma to a combination of bispecific antibodies and saporin. Leuk Res (1996) 0.83
Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice. Cancer Res (1997) 0.81
Cytosolic immunization allows the expression of preATF-saporin chimeric toxin in eukaryotic cells. FASEB J (2000) 0.80
Signal peptide-regulated toxicity of a plant ribosome-inactivating protein during cell stress. Plant J (2010) 0.80
Engineering a switchable toxin: the potential use of PDZ domains in the expression, targeting and activation of modified saporin variants. Protein Eng Des Sel (2009) 0.78